ERRATUM: TREATMENT OF GRAM-POSITIVE NOSOCOMIAL PNEUMONIA: PROSPECTIVE RANDOMIZED COMPARISON OF QUINUPRISTIN/ DALFOPRISTIN VERSUS VANCOMYCIN

	ARTICLE

TOP ARTICLE REFERENCES

To the Editor :

Since the publication of this paper, it has come to my attention that a number of numerical errors appeared, principally in the tables. None of these errors alters the conclusions of the paper or our confidence in them. However, we would be very grateful if the record could be set straight by the publication of an erratum giving the correct data.

The errors are as follows:

Table b:2bix of the p values shown are incorrect; the right-hand column should read: 0.97, 0.74, 0.76, 0.55, 0.79, 0.59, 0.91, 0.74, 0.33, 0.38, 0.47, 0.01. The percentage of patients in the quinupristin/dalfopristin group on mechanical ventilation (row 9) should be 80.4, not 70.4.

Table 3: Several of the numbers in this table are incorrect. A corrected version of the table appears below.

Table b:6bhe clinical success rate for the all-treated population with a baseline pathogen, gram-positive only, quinupristin/dalfopristin group (row 4) should be 13/31, not 3/31. The clinical success rate for the all-treated population with a baseline pathogen, gram-negative only, quinupristin/dalfopristin group (row 5) should be 15/31 (48.4), not 5/31 (55.6). The clinical success rate for the all-treated population with a baseline pathogen, gram-negative only, vancomycin group (row 5) should be 15/27 (55.6), not 15/20 (75).

Table 7: The p value for the related adverse clinical events, nonvenous (line 3) should read < 0.01, not 0.10.

In the METHODS section, page 754, right-hand column, paragraph 1, line 11 should be < 10 squamous epithelial cells, not > 10 squamous epithelial cells.

I would like to further underline our conclusion that in this study, quinupristin/dalfopristin was shown to be equivalent to vancomycin in the treatment of nosocomial pneumonia due to gram-positive pathogens.

Hôpital Européen Georges Pompidou, Paris, France

1. Fagon J-Y, Patrick H, Haas DW, Torres A, Gibert C, Cheadle WG, Falcone RE, Anholm JD, Paganin F, Fabian TC, Lilienthal F. the Nosocomial Pneumonia Group. Treatment of gram-positive nosocomial pneumonia: prospective randomized comparison of quinupristin/ dalfopristin versus vancomycin. Am J Respir Crit Care Med 2000; 161: 753-762 [Abstract/Free Full Text].